For example, in treating conditions like macular degeneration, where frequent anti-vascular endothelial growth factor (VEGF) injections are typically required, MNs can deliver the drug in a controlled manner over time, maintaining therapeutic levels and minimizing the frequency of injections12. This evidence concerns the gene VEGFA and macular degeneration.